Amarin Corp Plcuk (AMRN) Retained Earnings (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Retained Earnings of -$1.7 billion for Q1 2026, down 2.0% YoY from -$1.8 billion in Q1 2025, and down 0.62% sequentially from -$1.7 billion in Q4 2025.
Amarin Corp Plcuk (AMRN) Retained Earnings (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Retained Earnings across 17 years of filings, most recently posting -$1.7 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 2.0% year-over-year to -$1.7 billion; the TTM figure through Mar 2026 stood at -$1.7 billion (down 2.0% YoY), while the FY2025 annual figure was -$1.7 billion, down 2.33% from the prior year.
- Retained Earnings slipped to -$1.7 billion in Q1 2026, from -$1.7 billion in the prior quarter.
- Over the last five years, Retained Earnings for AMRN reached as high as -$1.5 billion in Q1 2022 and fell as low as -$1.7 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$1.6 billion (2024), against an average of -$1.6 billion.
- The widest YoY moves for Retained Earnings: up 1.55% in 2022, down 7.44% in 2022.
- A 5-year view of Retained Earnings shows it stood at -$1.5 billion in 2022, then decreased by 3.87% to -$1.6 billion in 2023, then slipped by 5.18% to -$1.7 billion in 2024, then dropped by 2.33% to -$1.7 billion in 2025, then retreated by 0.62% to -$1.7 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.7 billion, -$1.7 billion, and -$1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 29.51 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -14.83 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -17.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 9.67 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 66.72 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -190.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 78.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -7.20 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | -1.72 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.72 Bn |
| Dec 31, 2025 | -1.71 Bn |
| Sep 30, 2025 | -1.71 Bn |
| Jun 30, 2025 | -1.70 Bn |
| Mar 31, 2025 | -1.68 Bn |
| Dec 31, 2024 | -1.67 Bn |
| Sep 30, 2024 | -1.62 Bn |
| Jun 30, 2024 | -1.59 Bn |
| Mar 31, 2024 | -1.60 Bn |
| Dec 31, 2023 | -1.59 Bn |
| Sep 30, 2023 | -1.58 Bn |
| Jun 30, 2023 | -1.56 Bn |
| Mar 31, 2023 | -1.54 Bn |
| Dec 31, 2022 | -1.53 Bn |
| Sep 30, 2022 | -1.53 Bn |
| Jun 30, 2022 | -1.52 Bn |
| Mar 31, 2022 | -1.45 Bn |
| Dec 31, 2021 | -1.42 Bn |
| Sep 30, 2021 | -1.44 Bn |
| Jun 30, 2021 | -1.42 Bn |